$0.39
0.00% day before yesterday
Nasdaq, Aug 30, 01:00 am CET
ISIN
US04746L1044
Symbol
ATHA

Athira Pharma Inc Stock price

$0.39
+0.00 0.10% 1M
-0.02 5.38% 6M
-0.20 33.77% YTD
-2.68 87.34% 1Y
-2.95 88.37% 3Y
-16.61 97.71% 5Y
-16.61 97.71% 10Y
-16.61 97.71% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.01 1.74%
ISIN
US04746L1044
Symbol
ATHA
Industry

Key metrics

Basic
Market capitalization
$15.3m
Enterprise Value
$-14.5m
Net debt
positive
Cash
$29.8m
Shares outstanding
39.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.5
Financial Health
Equity Ratio
76.3%
Return on Equity
-216.2%
ROCE
-190.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-61.0m | $-70.7m
EBIT
$-62.0m | $-30.6m
Net Income
$-59.9m | $-28.3m
Free Cash Flow
$-70.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
48.6% | 26.2%
EBIT
48.2% | 68.4%
Net Income
47.2% | 70.8%
Free Cash Flow
28.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.6
FCF per Share
$-1.8
Short interest
2.7%
Employees
26
Rev per Employee
$0.0
Show more

Is Athira Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Athira Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Athira Pharma Inc forecast:

5x Hold
63%
3x Sell
38%

Analyst Opinions

8 Analysts have issued a Athira Pharma Inc forecast:

Hold
63%
Sell
38%

Financial data from Athira Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
17% 17%
-
- Research and Development Expense 35 35
63% 63%
-
-61 -61
49% 49%
-
- Depreciation and Amortization 0.97 0.97
0% 0%
-
EBIT (Operating Income) EBIT -62 -62
48% 48%
-
Net Profit -60 -60
47% 47%
-

In millions USD.

Don't miss a Thing! We will send you all news about Athira Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Athira Pharma Inc Stock News

Positive
The Motley Fool
25 days ago
Athira Pharma (ATHA -2.38%), a biopharmaceutical company developing drugs for neurodegenerative diseases, released its second quarter results on August 7, 2025. The update centered on its cost containment, strategic pipeline refocus, and progress with its lead candidate, ATH-1105.
Neutral
GlobeNewsWire
4 months ago
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
Neutral
GlobeNewsWire
4 months ago
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25

Company Profile

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company was founded by Leen Kawas and Joseph Harding in 2011 and is headquartered in Seattle, WA.

Head office United States
CEO Mark Litton
Employees 26
Founded 2011
Website www.athira.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today